How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
复制标题
DOI：
10.1007/s00520-022-07484-7
复制
发表时间：
2022-12-16
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
人们对癌症治疗耐受性的患者报告测量方法越来越感兴趣。一种衡量困扰程度的总体指标，即癌症治疗功能评估量表（FACT）中的GP5条目（“我受到治疗副作用的困扰”）可能在监管、研究和临床应用方面具有实用价值。为了解该条目在衡量治疗耐受性方面的适用性，我们对3组癌症患者样本就该条目进行了认知访谈。
对患有卵巢癌（研究1：N = 21；正在接受治疗）、淋巴瘤（研究2：N = 14；正在接受治疗）以及结直肠癌或肺癌（研究3：N = 16；未接受过治疗）的患者就GP5的可理解性及其与治疗副作用的相关性进行了访谈。还评估了患者在回答GP5时的思考内容。在所有研究中，访谈都包括结构化问题和开放式问题。对定性数据进行编码以提取主题，并对结构化问题的回答进行统计。
大多数正在接受治疗的患者（研究1和2）表示GP5条目的措辞恰当（88%），其含义清晰（97%）。他们对自己的回答非常有信心或有信心（97%），并表示GP5与他们的癌症经历相关（97%）。在回答GP5时，患者考虑了他们的治疗和具体的副作用。很大比例（40%）未接受过治疗的患者（研究3）表示GP5与他们的癌症治疗无关，且最大比例的患者在回答GP5时考虑的是负面副作用预期。
这项研究证实GP5是治疗耐受性的一个有用指标，对癌症患者有意义，尤其是对那些已经开始接受治疗的患者。
There is increasing interest in patient-reported measures of cancer treatment tolerability. A global measure of bother, the FACT GP5 item (“I am bothered by side effects of treatment”) is potentially useful for regulatory, research, and clinical use. To understand this item’s appropriateness for capturing treatment tolerability, we conducted cognitive interviews on this item with 3 samples of cancer patients. Patients with ovarian cancer (Study 1: N = 21; on treatment), lymphoma (Study 2: N = 14; on treatment), and colorectal or lung cancer (Study 3: N = 16; treatment naïve) were interviewed about GP5’s understandability and relevance to their treatment side effects. What patients think about when answering GP5 was also assessed. In all studies, the interview included both structured and open-ended questions. Qualitative data were coded to extract themes and responses to structured questions were tallied. Most patients on treatment (Studies 1 and 2) reported that the GP5 item wording is appropriate (88%) and its meaning is clear (97%). They were very confident or confident in their response (97%) and stated that GP5 was relevant to their cancer experience (97%). When answering GP5, patients considered their treatment and specific side effects. A large proportion (40%) of the treatment-naïve (Study 3) patients reported that GP5 was not relevant to their cancer treatment, and the largest proportion responded to GP5 thinking of negative side effect expectancies. This study provides assurance that GP5 is a useful indicator of treatment tolerability, and is meaningful to people with cancer, especially once they have started treatment.
登录
查看更多内容
影响因子：
28.4
作者：
Dueck AC;Mendoza TR;Mitchell SA;Reeve BB;Castro KM;Rogak LJ;Atkinson TM;Bennett AV;Denicoff AM;O'Mara AM;Li Y;Clauser SB;Bryant DM;Bearden JD 3rd;Gillis TA;Harness JK;Siegel RD;Paul DB;Cleeland CS;Schrag D;Sloan JA;Abernethy AP;Bruner DW;Minasian LM;Basch E;National Cancer Institute PRO-CTCAE Study Group
通讯作者：
National Cancer Institute PRO-CTCAE Study Group
影响因子：
4.5
作者：
Kluetz, Paul G.;Kanapuru, Bindu;Coons, Stephen Joel
通讯作者：
Coons, Stephen Joel
影响因子：
10.3
作者：
Basch, Ethan;Jia, Xiaoyu;Schrag, Deborah
通讯作者：
Schrag, Deborah
影响因子：
45.3
作者：
Loprinzi, Charles L.;Lacchetti, Christina;Hershman, Dawn L.
通讯作者：
Hershman, Dawn L.
影响因子：
45.3
作者：
Hahn, EA;Glendenning, GA;Cella, D
通讯作者：
Cella, D